| Caitlyn Tucker Gallenstein, | |
|
491 Tucker Dr, Maysville, KY 41056-9111 | |
| (606) 759-4005 | |
| Not Available |
| Full Name | Caitlyn Tucker Gallenstein |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 491 Tucker Dr, Maysville, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639729536 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 252563 (Kentucky) | Secondary |
| 235Z00000X | Speech-language Pathologist | 264688 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlyn Tucker Gallenstein, 491 Tucker Dr, Maysville, KY 41056-9111 Ph: () - | Caitlyn Tucker Gallenstein, 491 Tucker Dr, Maysville, KY 41056-9111 Ph: (606) 759-4005 |
News Archive
Hospital emergency departments play a growing role in the U.S. health care system, accounting for a rising proportion of hospital admissions and serving increasingly as an advanced diagnostic center for primary care physicians, according to a new RAND Corporation study.
A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.
› Verified 3 days ago
Ms. Hollice Erin Huber, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6127 Key Pike, Maysville, KY 41056 Phone: 606-759-9355 | |
Theresa Mccoy, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 620 Parker Rd, Maysville, KY 41056 Phone: 606-564-4085 | |
Crystal Reed, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6105 Key Pike, Maysville, KY 41056 Phone: 606-407-1003 | |
Mrs. Katie Grimes Ellis, MAED, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 667 Kings Way, Maysville, KY 41056 Phone: 606-375-5308 |